Sign in
CompletedNo phase

PDO Thread Embedding Plus Binh Vi Tablets for Gastroesophageal Reflux Disease

Key facts

Who runs it
University of Medicine and Pharmacy at Ho Chi Minh City
Where
Vietnam1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
86 people enrolled
Started
20 Mar 2026
Ended
31 Aug 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • PDO Thread Embedding
  • Esomeprazole 40 mg Oral Tablet
  • Binh Vi Tablets
Record updated
2 November 2026

Who can take part

Age
18 years to 60 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Adults aged 18 to under 60 years presenting for examination and treatment at Ho Chi Minh City Traditional Medicine Hospital, regardless of sex or occupation
  • Diagnosis of gastroesophageal reflux disease (GERD), defined as a GerdQ score of 8 or higher, with heartburn and/or regurgitation occurring at least 2 days per week, and an indication for standard-dose proton pump inhibitor (PPI) therapy according to the 2022 American College of Gastroenterology (ACG) and 2017 World Gastroenterology Organisation (WGO) guidelines
  • Not currently receiving treatment for GERD
  • Willingness to participate in the study and comply with the treatment regimen

Who cannot take part

  • Use of GERD medication within the specified washout periods before screening: PPIs within 14 days; histamine-2 receptor antagonists or prokinetics within 10 days; alginate-containing medications or antacids within 3 days; or herbal medicines for GERD at least 2 days per week
  • Receipt of traditional medicine treatment for GERD within 14 days before screening
  • History of esophageal and/or gastrointestinal surgery
  • Any contraindication to acupoint thread embedding according to the 2013 Vietnamese Ministry of Health guidance, including an acute medical emergency, severe physical debilitation, reduced resistance, pregnancy, infection or skin disease at the acupoint sites, or allergy to absorbable sutures or acupuncture needles
  • History of adverse reactions to proton pump inhibitors (PPIs), including reactions to formulation excipients
  • Current use of anticoagulants or a coagulation disorder due to another medical condition
  • Psychiatric illness or dementia
  • Known inflammatory bowel disease; serious hepatic, renal, respiratory, or cardiovascular disease; serious comorbid conditions; rare hereditary disorders (including fructose intolerance, glucose-galactose malabsorption, or congenital sucrase-isomaltase deficiency); or a history of drug or alcohol abuse
  • Current use of medications that may interfere with GERD treatment or assessment, including systemic glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), calcium channel blockers, anticholinergics, bisphosphonates, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, tetracyclines, HIV protease inhibitors, rifampin, potassium supplements, iron, quinidine, zidovudine, alpha-adrenergic agents, beta-2 adrenergic agonists, benzodiazepines, barbiturates, dopamine, estrogens, progesterone, opioid analgesics, nitrates, prostaglandins, or theophylline
  • Clinical alarm symptoms, including dysphagia, odynophagia, recurrent bronchial symptoms, aspiration pneumonia, dyspnea, recurrent or persistent cough, gastrointestinal bleeding, frequent nausea and/or vomiting, persistent pain, ongoing unintentional weight loss, lymphadenopathy, an epigastric mass, newly developed atypical symptoms between ages 45 and 55, or a family history of carcinoma of the esophagus or stomach
  • Current participation in another interventional study

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if PDO thread embedding combined with Binh Vi tablets and Esomeprazole works better than Binh Vi tablets and Esomeprazole alone in treating gastroesophageal reflux disease (GERD) in adults.

Read full original descriptionShow less

The main questions it aims to answer are:

* Does adding PDO thread embedding improve GERD symptoms more effectively? * Does the combined treatment improve participants' quality of life? * What adverse effects may occur during PDO thread embedding? Researchers will compare PDO thread embedding combined with Esomeprazole 40 mg and Binh Vi tablets to Esomeprazole 40 mg and Binh Vi tablets alone to evaluate symptom improvement, clinical response, quality of life, and safety.

Participants will:

* Be randomly assigned to receive either PDO thread embedding plus Esomeprazole 40 mg and Binh Vi tablets, or Esomeprazole 40 mg and Binh Vi tablets alone. * Receive treatment for 4 weeks. Participants in the PDO thread embedding group will receive 2 sessions, one every 2 weeks. * Visit the clinic for treatment and checkups. * Complete questionnaires about GERD symptoms and quality of life at the start of the study, at 2 weeks, and at 4 weeks.

The 2 groups in the trial

  • PDO Thread Embedding + Esomeprazole 40 mg + Binh Vi TabletsTreatment being tested

    Participants receive PDO thread embedding twice over 4 weeks, once every 2 weeks, in addition to Esomeprazole 40 mg and Binh Vi tablets.

    Treatment: PDO Thread Embedding, Esomeprazole 40 mg Oral Tablet, and Binh Vi Tablets

  • Esomeprazole 40 mg + Binh Vi TabletsExisting treatment, for comparison

    Participants receive Esomeprazole 40 mg and Binh Vi tablets alone for 4 weeks, without PDO thread embedding.

    Treatment: Esomeprazole 40 mg Oral Tablet and Binh Vi Tablets

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluation of the Effectiveness of PDO Thread Embedding Combined With Binh Vi Tablets in the Treatment of Gastroesophageal Reflux Disease (GERD)
Record updated
2 November 2026